Cargando…

Group B Streptococcus Engages an Inhibitory Siglec through Sialic Acid Mimicry to Blunt Innate Immune and Inflammatory Responses In Vivo

Group B Streptococcus (GBS) is a common agent of bacterial sepsis and meningitis in newborns. The GBS surface capsule contains sialic acids (Sia) that engage Sia-binding immunoglobulin-like lectins (Siglecs) on leukocytes. Here we use mice lacking Siglec-E, an inhibitory Siglec of myelomonocytic cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yung-Chi, Olson, Joshua, Beasley, Federico C., Tung, Christine, Zhang, Jiquan, Crocker, Paul R., Varki, Ajit, Nizet, Victor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879367/
https://www.ncbi.nlm.nih.gov/pubmed/24391502
http://dx.doi.org/10.1371/journal.ppat.1003846
_version_ 1782297971879051264
author Chang, Yung-Chi
Olson, Joshua
Beasley, Federico C.
Tung, Christine
Zhang, Jiquan
Crocker, Paul R.
Varki, Ajit
Nizet, Victor
author_facet Chang, Yung-Chi
Olson, Joshua
Beasley, Federico C.
Tung, Christine
Zhang, Jiquan
Crocker, Paul R.
Varki, Ajit
Nizet, Victor
author_sort Chang, Yung-Chi
collection PubMed
description Group B Streptococcus (GBS) is a common agent of bacterial sepsis and meningitis in newborns. The GBS surface capsule contains sialic acids (Sia) that engage Sia-binding immunoglobulin-like lectins (Siglecs) on leukocytes. Here we use mice lacking Siglec-E, an inhibitory Siglec of myelomonocytic cells, to study the significance of GBS Siglec engagement during in vivo infection. We found GBS bound to Siglec-E in a Sia-specific fashion to blunt NF-κB and MAPK activation. As a consequence, Siglec-E-deficient macrophages had enhanced pro-inflammatory cytokine secretion, phagocytosis and bactericidal activity against the pathogen. Following pulmonary or low-dose intravenous GBS challenge, Siglec-E KO mice produced more pro-inflammatory cytokines and exhibited reduced GBS invasion of the central nervous system. In contrast, upon high dose lethal challenges, cytokine storm in Siglec-E KO mice was associated with accelerated mortality. We conclude that GBS Sia mimicry influences host innate immune and inflammatory responses in vivo through engagement of an inhibitory Siglec, with the ultimate outcome of the host response varying depending upon the site, stage and magnitude of infection.
format Online
Article
Text
id pubmed-3879367
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38793672014-01-03 Group B Streptococcus Engages an Inhibitory Siglec through Sialic Acid Mimicry to Blunt Innate Immune and Inflammatory Responses In Vivo Chang, Yung-Chi Olson, Joshua Beasley, Federico C. Tung, Christine Zhang, Jiquan Crocker, Paul R. Varki, Ajit Nizet, Victor PLoS Pathog Research Article Group B Streptococcus (GBS) is a common agent of bacterial sepsis and meningitis in newborns. The GBS surface capsule contains sialic acids (Sia) that engage Sia-binding immunoglobulin-like lectins (Siglecs) on leukocytes. Here we use mice lacking Siglec-E, an inhibitory Siglec of myelomonocytic cells, to study the significance of GBS Siglec engagement during in vivo infection. We found GBS bound to Siglec-E in a Sia-specific fashion to blunt NF-κB and MAPK activation. As a consequence, Siglec-E-deficient macrophages had enhanced pro-inflammatory cytokine secretion, phagocytosis and bactericidal activity against the pathogen. Following pulmonary or low-dose intravenous GBS challenge, Siglec-E KO mice produced more pro-inflammatory cytokines and exhibited reduced GBS invasion of the central nervous system. In contrast, upon high dose lethal challenges, cytokine storm in Siglec-E KO mice was associated with accelerated mortality. We conclude that GBS Sia mimicry influences host innate immune and inflammatory responses in vivo through engagement of an inhibitory Siglec, with the ultimate outcome of the host response varying depending upon the site, stage and magnitude of infection. Public Library of Science 2014-01-02 /pmc/articles/PMC3879367/ /pubmed/24391502 http://dx.doi.org/10.1371/journal.ppat.1003846 Text en © 2014 Chang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Chang, Yung-Chi
Olson, Joshua
Beasley, Federico C.
Tung, Christine
Zhang, Jiquan
Crocker, Paul R.
Varki, Ajit
Nizet, Victor
Group B Streptococcus Engages an Inhibitory Siglec through Sialic Acid Mimicry to Blunt Innate Immune and Inflammatory Responses In Vivo
title Group B Streptococcus Engages an Inhibitory Siglec through Sialic Acid Mimicry to Blunt Innate Immune and Inflammatory Responses In Vivo
title_full Group B Streptococcus Engages an Inhibitory Siglec through Sialic Acid Mimicry to Blunt Innate Immune and Inflammatory Responses In Vivo
title_fullStr Group B Streptococcus Engages an Inhibitory Siglec through Sialic Acid Mimicry to Blunt Innate Immune and Inflammatory Responses In Vivo
title_full_unstemmed Group B Streptococcus Engages an Inhibitory Siglec through Sialic Acid Mimicry to Blunt Innate Immune and Inflammatory Responses In Vivo
title_short Group B Streptococcus Engages an Inhibitory Siglec through Sialic Acid Mimicry to Blunt Innate Immune and Inflammatory Responses In Vivo
title_sort group b streptococcus engages an inhibitory siglec through sialic acid mimicry to blunt innate immune and inflammatory responses in vivo
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879367/
https://www.ncbi.nlm.nih.gov/pubmed/24391502
http://dx.doi.org/10.1371/journal.ppat.1003846
work_keys_str_mv AT changyungchi groupbstreptococcusengagesaninhibitorysiglecthroughsialicacidmimicrytobluntinnateimmuneandinflammatoryresponsesinvivo
AT olsonjoshua groupbstreptococcusengagesaninhibitorysiglecthroughsialicacidmimicrytobluntinnateimmuneandinflammatoryresponsesinvivo
AT beasleyfedericoc groupbstreptococcusengagesaninhibitorysiglecthroughsialicacidmimicrytobluntinnateimmuneandinflammatoryresponsesinvivo
AT tungchristine groupbstreptococcusengagesaninhibitorysiglecthroughsialicacidmimicrytobluntinnateimmuneandinflammatoryresponsesinvivo
AT zhangjiquan groupbstreptococcusengagesaninhibitorysiglecthroughsialicacidmimicrytobluntinnateimmuneandinflammatoryresponsesinvivo
AT crockerpaulr groupbstreptococcusengagesaninhibitorysiglecthroughsialicacidmimicrytobluntinnateimmuneandinflammatoryresponsesinvivo
AT varkiajit groupbstreptococcusengagesaninhibitorysiglecthroughsialicacidmimicrytobluntinnateimmuneandinflammatoryresponsesinvivo
AT nizetvictor groupbstreptococcusengagesaninhibitorysiglecthroughsialicacidmimicrytobluntinnateimmuneandinflammatoryresponsesinvivo